ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids (fats and cholesterol). The combined results were presented as a late-breaking presentation at the 49th Annual European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) congress in Paris.

Results from the combined IMPENDIA/EDEN trials showed that a low-glucose PD regimen led to clinically and statistically significant reductions in serum levels of HbA1c (the standard marker for assessing blood glucose control) in adult PD patients with diabetes. In the studies, significant reductions also were seen with certain lipid parameters including serum triglycerides (type of lipid or fat found in the blood), VLDL-cholesterol and apolipoprotein B (a protein that helps form LDL, or bad cholesterol, in blood) following a low-glucose PD regimen.

"A low-glucose prescription should be considered when managing diabetic patients on peritoneal dialysis," said Joanne Bargman, MD, University Health Network and professor of Medicine at the University of Toronto and presenting study investigator. "The data demonstrate low glucose PD regimens may be beneficial in aiding the management of glucose and lipid levels in diabetic PD patients."

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2020, April 03). ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20120528/ESRD-patients-with-diabetes-may-benefit-from-Baxters-low-glucose-PD-regimen.aspx.

  • MLA

    Baxter International Inc.. "ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20120528/ESRD-patients-with-diabetes-may-benefit-from-Baxters-low-glucose-PD-regimen.aspx>.

  • Chicago

    Baxter International Inc.. "ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen". News-Medical. https://www.news-medical.net/news/20120528/ESRD-patients-with-diabetes-may-benefit-from-Baxters-low-glucose-PD-regimen.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2020. ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20120528/ESRD-patients-with-diabetes-may-benefit-from-Baxters-low-glucose-PD-regimen.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A